Group A Streptococcus
Vaccines Forecast
No vaccine exists today for Group A Streptococcus, yet severe GAS disease still kills more than half a million people a year worldwide, and 2022 brought the largest invasive GAS upsurge Europe has recorded in decades. The 2026 edition is complete, covering both Vaxcyte's VAX-A1 and GSK's own four-component Strep A candidate, now the field's two clinical-stage programmes. It is delivered as two separate forecast models: one for the Western opportunity in paediatric and older-adult indications, one for the developing world and rheumatic heart disease prevention. Licence either on its own, or both together.
- Format
- Executive presentation + Excel model
- Model options
- Two: Western / developing world
- Coverage
- Developed & ROW/emerging markets
- Indications
- Pharyngitis, iGAS, RHD, PSGN
- Forecast horizon
- To 2045
- Approach
- Value/volume demand model
- Edition
- 2026
- Availability
- Now available to order
severe GAS disease
heart disease globally
pharyngitis ("strep throat") a year
Phase I: Vaxcyte and GSK
A vast, under-recognised burden, and still no licensed vaccine
Group A Streptococcus is one of the highest-burden bacterial pathogens for which no vaccine yet exists. This review sets out the full spectrum of GAS disease and its global burden before turning to the R&D landscape now emerging around it.
Pathogen overview - Streptococcus pyogenes (GAS)
Group A Streptococcus (GAS), or Streptococcus pyogenes, is a Gram-positive organism commonly carried in the throat and on the skin. Colonisation is mostly harmless, but GAS causes a remarkably wide spectrum of disease and post-infectious sequelae. At the mild end sits pharyngitis, or "strep throat," and impetigo-type skin infection (pyoderma); at the severe end sits invasive GAS disease (iGAS), including necrotising fasciitis, and the post-streptococcal sequelae of acute rheumatic fever, rheumatic heart disease (RHD) and post-streptococcal glomerulonephritis. It is this breadth, spanning a routine childhood infection and a leading cause of acquired cardiovascular disease, that makes GAS such an unusual vaccine target.
The most widely cited global burden estimate puts severe GAS disease at at least 517,000 deaths a year worldwide. Rheumatic heart disease carries the greatest share of that burden, with 15.6 million prevalent cases, 282,000 new cases and 233,000 deaths annually, concentrated overwhelmingly in children and young adults in developing regions. Invasive GAS disease adds a further 663,000 new cases and 163,000 deaths a year. Beneath these severe endpoints lies an enormous base of milder disease: more than 111 million prevalent cases of GAS pyoderma and over 616 million incident cases of GAS pharyngitis annually. A new multicountry epidemiological study is now under way specifically because, more than fifteen years after the estimates above were first published, contemporary country-level burden data are still lacking, underscoring how underinvested GAS surveillance has been relative to its disease burden.
That underinvestment was thrown into sharp relief by Europe's 2022/23 invasive GAS upsurge, the largest in decades. England and Wales recorded 54,630 scarlet fever notifications in 2022, the highest since 1953, while invasive GAS cases rose to 2,892 (5.1 per 100,000), with 339 deaths, a case fatality rate of 11.7%, driven substantially by the emergent M1UK strain following a pandemic-era lull in circulation. The most recent seasonal update, covering the 2025/26 season through October 2025, shows invasive GAS notifications again running at the higher end of the expected range and following a similar early trajectory to 2022/23, alongside rising antimicrobial resistance: erythromycin resistance in sterile-site isolates reached 30% this season, up from 18% the previous season, and tetracycline resistance reached 48%, underscoring the growing case for a preventive vaccine rather than reliance on antibiotics alone.
From decades of failed attempts to two clinical candidates
GAS vaccine development has a long, difficult history, complicated by strain diversity and theoretical rheumatic fever cross-reactivity concerns. Vaxcyte's VAX-A1 and GSK's own four-component Strep A candidate have now both translated that decades-long research effort into human testing, within weeks of one another.
-
VaxcytePhase I, first-in-humanVAX-A1 Multivalent, conjugate-based
Vaxcyte dosed the first participant in a randomised, placebo-controlled Phase I trial in healthy adults in Australia on 2 June 2026, assessing safety, tolerability and initial immune responses, with topline data expected in the second half of 2027. In its 5 August 2026 second-quarter business update, Vaxcyte confirmed all Stage 1 dose-escalation participants had received the first of two planned doses, with Stage 2 to proceed once the trial's independent Data Safety Monitoring Board has reviewed unblinded Stage 1 safety and tolerability data. In its 4 November 2026 third-quarter business update, Vaxcyte confirmed the study has now advanced to Stage 2 following completion of that DSMB review, beginning sequential dosing of the Low and Mid Dose cohorts (each now receiving a third vaccination), while the High Dose cohort moves into a newly added Stage 3 subject to further pre-specified safety assessment and DSMB review; topline Phase I data remain expected in the second half of 2027. -
GSKPhase I, first-in-human, recruitingGSK four-component Strep A vaccine (Combo4) GAC-CRM197 conjugate + SLO, SpyCEP, SpyAD
Developed by the GSK Vaccines Institute for Global Health, this candidate combines the native GAS carbohydrate conjugated to CRM197 with three further antigens (SLO, SpyCEP, SpyAD). It is now in a first-in-human Phase I trial in healthy young adults aged 18 to 25 in Australia, comparing aluminium hydroxide and AS37 adjuvant formulations across three doses. -
Coefficient Giving & partnersPhilanthropic funding & field-buildingStrep A Vaccine Fund
Philanthropic funder Coefficient Giving launched a new multi-donor Strep A Vaccine Fund in May 2026, with anchor donors including Good Ventures, aiming to mobilise $200 million over five years (just over $140 million raised at launch) to double the number of GAS vaccine candidates in clinical trials and advance at least one to Phase III by 2030. -
Global research consortiaCoordination & surveillanceStrep A vaccine stakeholder initiatives
Broader academic and public health consortia continue to coordinate target product profile development, clinical development pathway design and stakeholder engagement to accelerate the wider GAS vaccine field beyond a single developer. -
Academic & public health bodiesEpidemiological groundworkMulticountry burden-of-disease study
A new multicountry epidemiological study is under way to refresh country-level GAS disease burden estimates, the evidence base that future vaccine investment cases, including this report's own model, will draw upon. -
UKHSA & national surveillanceActive surveillanceSeasonal iGAS/scarlet fever surveillance
National surveillance systems now track iGAS activity and antimicrobial resistance season by season, providing an increasingly granular real-world signal of shifting GAS strain dynamics and disease severity.
Vaxcyte's VAX-A1 and GSK's four-component Strep A candidate have both entered clinical trials within weeks of one another, a genuine field-defining moment after decades in which no candidate progressed beyond preclinical research. Two well-resourced developers now validating the category, rather than one, materially de-risks the commercial case for GAS vaccines. It arrives just as Europe's 2022/23 invasive GAS upsurge, and a similarly elevated 2025/26 season, have renewed public health urgency, and as rising antimicrobial resistance narrows the margin antibiotics alone can provide. The VacZine Analytics model quantifies the commercial opportunity this creates across both developed and ROW/emerging markets under multiple pipeline-progression scenarios.
Two model options - the Western opportunity, and rheumatic heart disease
GAS is not one market. The Western commercial case and the developing-world public-health case have different target populations, different payers and different routes to market, so the 2026 edition is built as two self-contained forecast models rather than one blended global sheet. Licence either model on its own, or both together.
Paediatric and older-adult indications
US, Canada, Australia and the EU markets
For developers and investors positioning a GAS vaccine into high-income immunisation schedules, where pharyngitis prevention in children and invasive GAS disease in older adults are the two revenue-bearing indications. Volume and value are modelled against genuine schedule opportunities rather than an abstract addressable population.
- Multiple target-group options modelled side by side, spanning infant primary, early-childhood and pre-school placements, so the schedule decision can be tested rather than assumed
- A separately modelled older-adult invasive-disease scenario, held distinct from the paediatric schedule rather than folded into it, reflecting that these may be different products
- Schedule-fit mapping against current Western immunisation calendars, identifying where a GAS dose could realistically sit alongside existing visits
- Age-banded burden analysis setting invasive incidence and case fatality against the WHO preferred target age, including the mismatch that creates
- Cost-offset outputs by dosing option, so the schedule choice can be argued on health economics as well as coverage
- Launch sequencing from first high-income approval outward, benchmarked against the RSV and pneumococcal funding record
Rheumatic heart disease prevention
High-burden countries and regional aggregates
For the global-access and public-health case, where the prize is preventing acute rheumatic fever and rheumatic heart disease in children and young adults. This is where the mortality sits, and it behaves as a fundamentally different market: donor-financed, prequalification-gated and priced on an entirely different basis.
- A four-tier country framework rebuilt for 2026 from independent published burden analyses, not inherited from the previous edition
- Tiering tested across several burden measures, because mortality and prevalence rankings identify substantially different countries - a distinction most GAS market sizing misses
- Named volume and endemic countries modelled individually, with lower-materiality territories carried as regional lines to keep the model usable
- Birth-cohort sizing by single year of age from an established international demographic database, replacing the coarse regional aggregates of the previous edition
- Access-pathway modelling treating WHO prequalification, policy recommendation and the financing decision as sequential gates after stringent approval
- An LIC/MIC-first rollout scenario, for the case where a manufacturer launches in high-burden markets ahead of high-income ones
Six analytical layers - one commercial picture
This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, target product profile design, the R&D competitive landscape and scenario-based demand forecasting. Both model options draw on the same six analytical layers, applied to their own geographies and target populations.
Value/volume demand modelling out to 2045, split into a Western model covering the paediatric and older-adult indications and a developing-world model covering rheumatic heart disease.
Full review of Vaxcyte's VAX-A1 and GSK's four-component Strep A candidate, their trial designs and dosing schedules, plus the broader stakeholder and surveillance landscape.
Ideal target product profile assessment, dosing and target-group options, and where a GAS dose could sit in Western and EPI immunisation calendars.
Four first-entry scenarios - accelerated, base case, downside and an LIC/MIC-first pathway - each traced through to volume and value.
Full global burden review across pharyngitis, pyoderma, invasive GAS and post-streptococcal sequelae, updated with the 2022/23 and 2025/26 upsurge data.
Designed as an ideal tool to aid early-stage decision making in GAS vaccine development, investment and market entry planning.
A glimpse of the commercial model
The table below shows a partial view of the indication and geography framework running across the two model options. Full volume/value outputs, pricing assumptions, country tiering and uptake curves sit inside the licensed models.
| Indication | Geography | Target group | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| Pharyngitis ("strep throat") | Developed markets | Paediatric | Pre-licensure | Modelled |
| Rheumatic heart disease prevention | ROW / emerging markets | Paediatric & adolescent | Pre-licensure | Modelled |
| Invasive GAS (iGAS) | Developed markets | Older adults | Pre-licensure | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All geographies | All groups | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, in your choice of the Western model, the developing-world RHD model, or both.
- Executive presentation - disease background, global burden, target product profile, clinical development issues and full competitive environment review
- MS-Excel value/volume forecast model - annual demand outputs to 2045 across all relevant indications and regions, long enough to carry every launch scenario through to a mature uptake plateau
- Two model options - Model 1 for Western markets (paediatric and older-adult indications) and Model 2 for the developing world (rheumatic heart disease), licensable separately or together
- Target-group and schedule-fit analysis - multiple dosing and target-group options tested, with a separately modelled older-adult invasive-disease scenario
- Competitor intelligence - Vaxcyte's VAX-A1, GSK's four-component Strep A candidate and the broader stakeholder landscape
- Updated epidemiology module - global burden data alongside the 2022/23 and 2025/26 European iGAS upsurges and rising antimicrobial resistance
- Early decision-making support - ideal target product profile and market entrance strategy guidance for early-stage GAS vaccine planning
Built for organisations evaluating the GAS vaccine opportunity
Most valuable to teams assessing the Group A Streptococcus vaccine market against their own pipeline, BD ambitions or investment thesis, now that two candidates have entered the clinic.
Vaccine developers
Positioning, target product profile and commercial feasibility assessment for GAS candidates at any stage.
Corporate strategy & BD
Validate the size and structure of a market with no incumbent vaccine, now that VAX-A1 and GSK's candidate have both proven the category is investable.
Investors & analysts
Independent assessment of pipeline risk and commercial upside for due diligence on Vaxcyte, GSK and future GAS vaccine entrants.
Public health & immunisation programmes
The developing-world model is built for exactly this: tiered, country-level demand to support RHD-prevention and paediatric immunisation programme planning.
Researchers & academia
Comprehensive epidemiology and R&D landscape for grant, translational and rheumatic heart disease prevention planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions across public and private channels in both developed and emerging markets.
VacZine Analytics has tracked Respiratory vaccine markets since our earliest editions, positioning us to reassess the GAS vaccine opportunity the moment the field's first clinical candidates emerged. This is a genuinely comprehensive analysis with a wide geographic focus, spanning both Western developed markets and ROW/emerging markets, and it has been well received by clients across the field for the depth of its target product profile and clinical development review. Few groups have followed this historically underinvested market as closely, and that recognised, independent expertise underpins everything in the analysis.
The 2026 edition is now complete and published, incorporating current global burden data, the 2022/23 and 2025/26 European invasive GAS upsurges, and both Vaxcyte's VAX-A1 and GSK's four-component Strep A candidate, the field's first two vaccine candidates to enter clinical trials. The forecast is delivered as two model options - a Western model covering the paediatric and older-adult indications, and a developing-world model covering rheumatic heart disease prevention - reflecting our view that these are two genuinely different markets and should not be blended into a single global number. Either model can be licensed on its own, or both together; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Order the full report - or commission the answer you need
The 2026 edition of the MarketVIEW report on Group A Streptococcus vaccines is complete and available to order, as the Western model, the developing-world RHD model, or both. Single-licence and multi-user options are available. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc GAS vaccine analysis, and a briefing call is included on request.